BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20231532)

  • 1. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.
    Heinz J; Kropf S; Domröse U; Westphal S; Borucki K; Luley C; Neumann KH; Dierkes J
    Circulation; 2010 Mar; 121(12):1432-8. PubMed ID: 20231532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
    Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.
    Zoungas S; McGrath BP; Branley P; Kerr PG; Muske C; Wolfe R; Atkins RC; Nicholls K; Fraenkel M; Hutchison BG; Walker R; McNeil JJ
    J Am Coll Cardiol; 2006 Mar; 47(6):1108-16. PubMed ID: 16545638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
    Righetti M; Serbelloni P; Milani S; Ferrario G
    Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
    Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J;
    Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
    J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.
    Mann JF; Sheridan P; McQueen MJ; Held C; Arnold JM; Fodor G; Yusuf S; Lonn EM;
    Nephrol Dial Transplant; 2008 Feb; 23(2):645-53. PubMed ID: 18003666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients.
    Sombolos K; Fragia T; Natse T; Bartholomatos G; Karagianni A; Katsaris G; Christidou F; Bamichas G; Stangou M; Papagalanis N
    J Nephrol; 2002; 15(6):671-5. PubMed ID: 12495282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.
    Ebbing M; Bleie Ø; Ueland PM; Nordrehaug JE; Nilsen DW; Vollset SE; Refsum H; Pedersen EK; Nygård O
    JAMA; 2008 Aug; 300(7):795-804. PubMed ID: 18714059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of multivitamin supplementation on the homocysteine and methylmalonic acid blood concentrations in women over the age of 60 years.
    Wolters M; Hermann S; Hahn A
    Eur J Nutr; 2005 Mar; 44(3):183-92. PubMed ID: 15309436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
    Alvares Delfino VD; de Andrade Vianna AC; Mocelin AJ; Barbosa DS; Mise RA; Matsuo T
    Nutrition; 2007 Mar; 23(3):242-7. PubMed ID: 17321110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.
    House AA; Eliasziw M; Urquhart BL; Freeman DJ; Spence JD
    Am J Kidney Dis; 2004 Oct; 44(4):689-94. PubMed ID: 15384020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
    Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
    Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine lowering and cardiovascular events after acute myocardial infarction.
    Bønaa KH; Njølstad I; Ueland PM; Schirmer H; Tverdal A; Steigen T; Wang H; Nordrehaug JE; Arnesen E; Rasmussen K;
    N Engl J Med; 2006 Apr; 354(15):1578-88. PubMed ID: 16531614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated homocysteine levels in patients with end-stage renal disease.
    Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
    Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
    Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR
    Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
    Righetti M; Ferrario GM; Milani S; Serbelloni P; La Rosa L; Uccellini M; Sessa A
    Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.